Unknown

Dataset Information

0

Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting ?2 Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study.


ABSTRACT:

Introduction

In the prospective, observational, 16-week REACT study conducted between October 21, 2008 and May 12, 2011, we compared the real-world effectiveness of anti-inflammatory reliever and maintenance therapy with budesonide/formoterol (Symbicort® Turbuhaler) and maintenance therapy with fixed-dose fluticasone/salmeterol (Seretide®) plus as-needed, short-acting ?2 agonists (SABAs) in Taiwanese patients with inadequate asthma control.

Methods

Asthma control was assessed using the five-item Asthma Control Questionnaire (ACQ-5) and standardized pulmonary function testing. Assessments were performed at baseline and at weeks 4-5 and 12-16. Overall, we enrolled 842 patients at 11 clinics, 723 of whom were included in analyses (budesonide/formoterol, 563.3±1.3 ?g/d, n=551; fluticasone/salmeterol, 1013.8±1.4 ?g/d, n=172).

Results

At baseline, 72.5% and 27.5% of all patients had "partly" and "uncontrolled" asthma, respectively. Mean±SD ACQ-5 scores were 1.54±1.06 and 1.46±1.28 in the budesonide/formoterol and fluticasone/salmeterol groups, respectively. ACQ-5 scores significantly improved from baseline (ie, decreased) in both groups at weeks 4 and 16. ACQ-5 difference scores were significantly lower in the budesonide/formoterol group (-0.91±1.11) than the fluticasone/salmeterol group (-0.69±1.27) at the end of the study (p=0.027). Peak expiratory flow rate significantly improved from baseline in the budesonide/formoterol but not the fluticasone/salmeterol group at the end of the study. Severe exacerbation rates and medical resource utilization were comparable between the budesonide/formoterol and fluticasone/salmeterol groups.

Conclusion

Collectively, results indicate the real-world effectiveness of budesonide/formoterol anti-inflammatory reliever and maintenance therapy is better than fixed-dose fluticasone/salmeterol plus as-needed SABA.

Trial registration

ClinicalTrials.gov registration number: NCT00784953.

SUBMITTER: Cheng SL 

PROVIDER: S-EPMC7733383 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β<sub>2</sub> Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study.

Cheng Shih-Lung SL   Ho Ming-Lin ML   Lai Yun-Fa YF   Wang Hao-Chien HC   Hsu Jeng-Yuan JY   Liu Shih-Feng SF   Huang Ming-Shyang MS   Lee Cheng-Hung CH   Lin Ching-Hsiung CH   Hang Liang-Wen LW   Liu Yu-Chih YC   Yang Kuang-Yao KY   Wang Jia-Horng JH  

Drug design, development and therapy 20201208


<h4>Introduction</h4>In the prospective, observational, 16-week REACT study conducted between October 21, 2008 and May 12, 2011, we compared the real-world effectiveness of anti-inflammatory reliever and maintenance therapy with budesonide/formoterol (Symbicort<sup>®</sup> Turbuhaler) and maintenance therapy with fixed-dose fluticasone/salmeterol (Seretide<sup>®</sup>) plus as-needed, short-acting β<sub>2</sub> agonists (SABAs) in Taiwanese patients with inadequate asthma control.<h4>Methods</h4  ...[more]

Similar Datasets

| S-EPMC1924504 | biostudies-literature
| S-EPMC3298511 | biostudies-literature
| S-EPMC4008134 | biostudies-literature
| S-EPMC4545560 | biostudies-literature
| S-EPMC1920547 | biostudies-other
| S-EPMC4176847 | biostudies-literature
| S-EPMC6147211 | biostudies-literature
| S-EPMC4409772 | biostudies-literature
| S-EPMC7503413 | biostudies-literature
| S-EPMC2780558 | biostudies-literature